Bone Biologics Corp BBLGW
Nasdaq · XNAS · stock · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Chart by TradingView
3/9
Piotroski F — financial health
-33.74
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$3.1M | — | — | $5.4M |
| 2024 | — | -$4.1M | — | — | $3.5M |
| 2023 | — | -$8.9M | — | — | $2.9M |
| 2022 | — | -$1.5M | — | — | $5.9M |
| 2021 | — | -$1.6M | — | — | $6.6M |
| 2020 | $1.1B | -$1.8M | — | — | -$13.7M |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -33.74 (distress)
- Working capital / assets 0.928
- Retained earnings / assets -15.205
- EBIT / assets -0.558
- Equity / liabilities 12.847
Source: SEC EDGAR filings · CIK 0001419554 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.